C ardiovascular risk reduction therapy in diabetic patients reduces vascular events (1) by retarding atherosclerosis and improving vascular reactivity. Matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) are integral to the vascular changes of atheroma, and MMP-9 and TIMP-1 are raised in diabetes (2). We hypothesized that global risk reduction of intensified diabetes and cardiovascular risk management in type 2 diabetes would be associated with reductions in circulating markers of extracellular matrix turnover, namely MMP-9, TIMP-1, and TIMP-2.
C ardiovascular risk reduction therapy in diabetic patients reduces vascular events (1) by retarding atherosclerosis and improving vascular reactivity. Matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) are integral to the vascular changes of atheroma, and MMP-9 and TIMP-1 are raised in diabetes (2). We hypothesized that global risk reduction of intensified diabetes and cardiovascular risk management in type 2 diabetes would be associated with reductions in circulating markers of extracellular matrix turnover, namely MMP-9, TIMP-1, and TIMP-2.
RESEARCH DESIGN AND METHODS
Cross-sectional study Eighty-six patients with type 2 diabetes (3) and treated hypertension with serum creatinine Ͻ120 mmol/l were recruited from local clinics (Table 1) . Of these, 46% (n ϭ 36) had a clinical history of cardiovascular disease. Data from these patients were compared with 49 healthy control subjects. Ethical approval and informed consent were obtained. 
Interventional study

Laboratory analyses
Citrated venous blood was obtained and immediately centrifuged at 1,000g and 4°C for 20 min. Plasma was aliquoted and stored at Ϫ70°C for a batch analysis of MMP and TIMP by enzyme-linked immunosorbent assay (5).
Power calculations and statistical analysis
We hypothesized a minimum difference of half an SD between case and control subjects. To achieve this at 2pϽ0.025 and 1-␤ ϭ 0.85 required a minimum of 44 case and control subjects. We estimated that the treatment would produce a quarter SD difference in research indexes, and at 2p Ͻ 0.025 and 1-␤ ϭ 0.85, calculated a minimum requirement of 60 subjects. We used the Mann-Whitney test to compare the control subjects with the pretreatment group and the Wilcoxon's rank-sum test for pre-and posttreatment MMP/TIMP comparisons. Correlations were performed using the Spearman test. A P value of Ͻ0.05 was taken as statistically significant.
RESULTS -Patients and control subjects were of similar age, sex, smoking status, and BMI (Table 1) , but baseline systolic blood pressure and HbA 1c were higher while HDL was lower in the diabetic patients.
The circulating plasma levels of MMP-9, TIMP-1, and TIMP-2 were all significantly higher in the diabetic patients (Table 1) . Within diabetic patients, current smokers (n ϭ 14) had higher circulating TIMP-1 levels than nonsmokers (510 ng/ml [335-660] vs. 390 [290 -475] , P ϭ 0.017). There was a weak positive correlation between TIMP-1 and HbA 1c (r ϭ 0.214, P ϭ 0.048) only. CONCLUSIONS -Circulating MMP-9, TIMP-1, and TIMP-2 are raised in treated hypertensive patients with type 2 diabetes compared with normotensive control subjects, which is in keeping with extracellular matrix abnormalities present in this high-risk population.
Effects of intervention
TIMP-1 is an endogenous MMP inhibitor that may be involved in vascular matrix fibrosis (4) and has a role in left ventricular hypertrophy and diastolic dysfunction by reducing cardiac collagen type I turnover, thereby increasing cardiac mass and stiffness (4,5). Increased central and peripheral artery stiffness (6) occurs with diabetes (7), and higher circulating levels of TIMP-1 complement the hypothesis that altered TIMP-1 activities could be linked to arterial stiffness. Smokers have abnormal arterial compliance (8), and raised TIMP-1 levels could mirror increased vascular stiffness. Glucose and cholesterol reduction have both been shown to improve vascular compliance (9, 10) . The fall in TIMP-1 seen here by improvement in metabolic control raises the possibility of TIMP-1 as a marker of vascular composition in diabetes.
Recent reports have suggested a decrease in renal (11) and vascular tissue MMP-9 (12,13) and an increase in endothelial cell and macrophage MMP-9 in response to glucose (14) . Our findings suggest a total increase in MMP-9 in diabetes and that endothelium and macrophages may be partially responsible for this rise. The failure of MMP-9 (and TIMP-2) to fall may relate to the lack of change in blood pressure during intervention. Treatment with insulin (in obese nondiabetic subjects) can reduce MMP-9 and may also explain why circulating MMP-9 did not fall in our study (15) .
Diabetes is associated with abnormal angiogenesis (both impaired and/or excessive) and can impair the process of collateralization (16) . TIMP-2 may attenuate angiogenesis (17) . Increases in circulating TIMP-2 may reflect abnormal blood vessel formation. Manipulating this process may have some therapeutic potential.
A major limitation of this and many other studies is a lack of tissue-based measures. Unfortunately, obtaining human tissue is difficult, and venesection is often the only practical analysis. Furthermore, our patient group is heterogenous, and therefore, it is difficult to show in our group which particular intervention had the most effect. However, since most patients in routine clinical practice show similar profiles to our cohort, this point is of academic rather than clinical interest, as it is rare for such patients to present, and multifactorial intervention is the rule nowadays. This study suggests that further work in either human (in particular vascular compliance, which we were unable to measure) or animal models to further clarify the role of matrix in diabetes is clearly warranted. 
